Company Facts

SCROLL DOWN

Company Facts

Mission

Rainbow Holdings & Joint Ventures

🤔 Did you know, only 1% of your DNA is made up of genes?

The other 99% isn't genes, but it controls your risks for heart disease, stroke, diabetes, and high blood pressure. It also affects your look, nutrition, exercise, weight loss, and skin health.
We use whole genome & protein analysis, study all 20,000 genes in the 1% of your DNA, and the millions of changes in the other 99%!
We help you understand 100% of your DNA, your risks of major diseases, and help you prevent these health threats.

What we do:

Rainbow Genomics, established in 2016, uses genomic and 7000-blood protein testing to help doctors and patients to understand genetic variations, leading to improved treatment and health care outcomes.

Using All Your DNA & 7000 Proteins

Risk Assessment Made Easy. We figure out your long-term and immediate risks for critical disorders before they even start.
Personalized Prevention and Treatment. Working with hospitals and physician specialists, we offer personalized prevention and medical treatment, to manage risk and improve clinical outcome
Global Precision Medicine. We leverage our U.S. clinical & molecular testing infrastructure delivering precision medicine worldwide

Proteins - 4 Year Risks

Heart Attack, Stroke

Better Diet & Exercise

Weight Loss

based on your DNA

Rainbow Holdings and Joint Ventures

leverages our precision medicine platform

producing vertical human health businesses

how we do it

DNA

Genomics: The Detective - Tells us what might happen.
We determine risks of ~8000 human disorders that are caused by genetic abnormality
Using one million+ SNPs (single nucleotide polymorphisms), and multi-ethnic polygenic risk analysis, we determine disease risks associated with common chronic disorders such as heart attack, stroke, diabetes, and cancers, for Caucasians, Asians, mixed race patients and any racial groups.

Proteins

Proteomics: The Real Time Reporter - Tells us what’s happening now. It’s like a live health check-up that shows if heart attack or stroke is sneaking up.
Using 7000 proteins, we determine imminent 4-year risks of heart attack, stroke, diabetes, liver & kidney disease, cardio-respiratory health, and cancers.

Health Traits

Do Better. We use your DNA to guide diet and exercise improvement, food choices, leading to more effective weight loss and health living.

Precision Medicine

Pharmacogenomics: The Personal Pharmacist 💊 - Tells us how to fix it best.
Working with physicians, based on your DNA, we provide personalized treatment, find the best medicine for you, and avoid side effects.

Clinical Outcome

We deliver substantially-improved health outcome compared to traditional medical practices, resulted in quantifiable reductions in health care cost at institutional and national levels

Our vertical human health businesses

Our products and services are based on large-scale human genomics, proteomics , multi-omics diagnostics, and our proprietary biomarker-disease-treatment databases.

We offer advanced diagnostics, knowledge databases, personalized clinical analysis, and interventions, leading to new prevention and treatment paradigms that substantially reduce health care cost at institutional and national scales.

Mission

Rainbow Genomics, part of Rainbow Holdings, uses genetic and protein testing to help doctors and patients to understand genetic variations, leading to improved treatment and health care outcomes.

We are a pioneer in the commercialization of genomic- and protein-based, diagnostic and preventive health care solutions to individuals.
We are committed to providing clinically-validated and evidence-based, multi-modal testing to Asian, Caucasian and mixed-race patients.

Markets

Rainbow is a provider of genetic testing and protein-based risk assessment services.

We cover a range of health issues, including rare hereditary disorders in both children and adults, genetic testing for medication responses, and assessing common disease risks.

We co-developed clinical applications with our institutional partners, and deploy credible clinical assessment products through highly-effective channels, to address both the domestic and medical tourism markets in Hong Kong, Japan, and the U.S.

Our primary product -Exome Sequencing

All Your DNA & 7000 Proteins

Clinically-Actionable Reports

Genomics

The human genome consists of 3 billion nucleotides or “letters” of DNA.

Our whole genome sequencing test analyzes all 3 billion DNA letters, providing high-quality results, often matching or exceeding those from top U.S. and European medical institutions.
We report common disease risks and health traits to help our patients prevent serious conditions and live healthier lives.
If a patient is at high risk for a common disease, our 7000-blood-protein test can predict if this disease might happen soon.
Doctors use this detailed information to better treat or prevent disease progression.

Unlike many consumer genetic tests that provide hundreds of findings that lack clinical relevance, Rainbow's whole genome sequencing provides clinically-actionable results that doctors can use to manage, treat, or prevent disorders.

Proteomics

We are a leader in using 7000-protein analysis to better estimate both long-term and short-term disease risks. Our current diagnostic programs combine genetic testing and protein analysis to assess the risks for heart attacks, lung cancer, diabetes, and dementia.

Multi-Ethnic

Polygenic Risk Scores

Through our U.S. partnerships, we use advanced multi-ethnic genetic models to predict the risk of common diseases like diabetes, stroke, and heart attacks.

We lead in combining genetic testing for rare inherited diseases with risk scores for common chronic diseases important to public health.

Precision Medicine

for

Asian, Mixed-Race and ethnic-minority Patients

Unlike many genetic tests that use only a small number of genes, Rainbow analyzes the entire genome. This reduces the risk of missing important ethnic-specific genes. Many gene panels were designed using studies on Caucasian patients in the U.S. and Europe, and may not work well for Asian, mixed-race, and minority patients. Whole genome sequencing helps solve this issue.

Regulatory Compliance

Comply with U.S. Clinical Regulatory & Patient Privacy Standards

ACMG Guidelines

We follow the latest guidelines from the American College of Medical Genetics and Genomics (ACMG) for interpreting genetic tests. Our clinical partners provide reports that are reviewed and signed by board-certified medical directors or genetic specialists.

CAP-Accredited & CLIA-Certified Laboratories

All Rainbow tests are performed at CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified laboratories.

HIPAA/Patient Privacy

Patient data privacy – Rainbow follows the U.S. Health Insurance Portability and Accountability Act (HIPAA) privacy rules, established to protect the confidentiality of patients' individually identifiable health information.

Japanese Clinical Guidelines

Additional clinical interpretation provided by the Juntendo University Medical School is in compliance with Japan’s clinical testing guidelines

Our Operations

Operations

Our Operations

Operations

Rainbow Genomics maintains operations in the U.S. and Hong Kong.

Our English-speaking, Hong Kong-based project managers work closely with ordering physicians to collect patient samples, manage testing process, and coordinate physician report delivery.
Our partner laboratories, U.S. and Japanese medical institutions support the entire clinical testing process.

Our genetic counselors and physician specialists provide multilingual (English with Japanese, Mandarin or Cantonese) genetic counseling to our patients, and consultation to physicians in local communities.

< Back